87
Participants
Start Date
December 18, 2017
Primary Completion Date
March 13, 2020
Study Completion Date
June 3, 2020
Fremanezumab
Fremanezumab will be administered per dose and schedule specified in the arm.
Placebo
Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Teva Investigational Site 14047, New York
Teva Investigational Site 14118, The Bronx
Teva Investigational Site 14119, Albany
Teva Investigational Site 14229, Amherst
Teva Investigational Site 14040, Pittsburgh
Teva Investigational Site 14064, Philadelphia
Teva Investigational Site 14044, Morgantown
Teva Investigational Site 14114, Durham
Teva Investigational Site 14059, Salisbury
Teva Investigational Site 14063, Miami
Teva Investigational Site 14041, North Miami
Teva Investigational Site 14056, Tampa
Teva Investigational Site 14230, Nashville
Teva Investigational Site 14058, Louisville
Teva Investigational Site 14067, Indianapolis
Teva Investigational Site 14057, Riverwoods
Teva Investigational Site 14046, St Louis
Teva Investigational Site 14043, Springfield
Teva Investigational Site 14048, Little Rock
Teva Investigational Site 30236, Little Rock
Teva Investigational Site 14050, Waco
Teva Investigational Site 14065, Phoenix
Teva Investigational Site 14053, Los Angeles
Teva Investigational Site 14052, Long Beach
Teva Investigational Site 14060, San Diego
Teva Investigational Site 14054, San Francisco
Teva Investigational Site 14049, Portland
Teva Investigational Site 14113, Spokane
Teva Investigational Site 14069, Scottsdale
Teva Investigational Site 14045, Fairfield
Teva Investigational Site 14061, Waltham
Teva Investigational Site 14051, Kansas City
Teva Investigational Site 14055, Dallas
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY